Amryt Pharma plc (AMYT) Tops Q2 EPS by 2c

Amryt Pharma plc (NASDAQ: AMYT) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $68.5 million versus the consensus estimate of $64.21 million.

GUIDANCE:

Amryt Pharma plc sees FY2022 revenue of $260-270 million, versus the consensus of $269 million.

For earnings history and earnings-related data on Amryt Pharma plc (AMYT) click here.

You May Also Be Interested In

• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight